The effect of cyclodextrins on chemical and physical stability of glucagon and characterization of glucagon/γ-CD inclusion complexes

Journal of Pharmaceutical Sciences

Volumn 97, Issue 7, 2008, Pages 2720-2729

  Matilainen, Laura ^a   Larsen, Kim Lambertsen ^b   Wimmer, Reinhard ^b   Keski Rahkonen, Pekka ^a   Auriola, Seppo ^a   Järvinen, Tomi ^a   Jarho, Pekka ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b AALBORG UNIVERSITY   (Denmark)

Author keywords

Complexation; Cyclodextrins; Glucagon; NMR spectroscopy; Peptides; Stability

Indexed keywords

AMINO ACID; CYCLODEXTRIN; GAMMA CYCLODEXTRIN; GLUCAGON;

ARTICLE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NUCLEAR MAGNETIC RESONANCE; PH; ULTRAVIOLET RADIATION;

EID: 52449107762     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21209     Document Type: Article

References (38)

1. United States Pharmacopeial Convention. 2003. USP27. 1st ed. Rockville, MD: United States Pharmacopeial Convention.
2. Joshi AB, Rus E, Kirsch LE. 2000. The degradation pathways of glucagon in acidic solutions. Int J Pharm 203:115-125.
3. Beaven GH, Gratzer WB, Davies HG. 1969. Formation and structure of gels and fibrils from glucagon. Eur J Biochem 11:37-42.
4. Onoue S, Ohshima K, Debari K, Koh K, Shioda S, Iwasa S, Kashimoto K, Yajima T. 2004. Mishandling of the therapeutic peptide glucagon generates cytotoxic amyloidogenic fibrils. Pharm Res 21: 1274-1283.
5. Frömming K-H, Szejtli J. 1994. Cyclodextrins in pharmacy. Dordrecht: Kluwer Academic Publishers.
6. Aachmann FL, Otzen DE, Larsen KL, Wimmer R. 2003. Structural background of cyclodextrin-protein interactions. Protein Eng 16:905-912.
7. Matsubara K, Irie T, Uekama K. 1997. Spectroscopic characterization of the inclusion complex of a luteinizing hormone-releasing hormone agonist, buserelin acetate, with dimethyl-beta-cyclodextrin. Chem Pharm Bull 45:378-383.
8. Irie T, Uekama K. 1999. Cyclodextrins in peptide and protein delivery. Adv Drug Deliv Rev 36:101-123.
9. Irie T, Uekama K. 1997. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci 86:147-162.
10. Challa R, Ahuja A, Ali J, Khar RK. 2005. Cyclodextrins in drug delivery: An updated review. AAPS PharmSciTech 6:E329-E357.
11. Sakr F. 1995. Nasal administration of glucagon combined with dimethyl-β-cyclodextrin: Comparison of pharmacokinetics and pharmacodynamics of spray and powder formulations. Int J Pharm 132:189-194.
12. Marttin E, Verhoef JC, Merkus FW. 1998. Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs. J Drug Target 6:17-36.
13. Hwang TL, Shaka AJ. 1995. Water suppression that works. Excitation sculpting using arbitrary wave-forms and pulsed-field gradients. J Magn Reson A 112:275-279.
14. Wüthrich K. 1986. NMR of proteins and nucleic acids. New York: Wiley.
15. Bartels C, Xia T, Billeter M, Güntert P, Wüthrich K. 1995. The program XEASY for computer-supported NMR spectral analysis of biological macromolecules. J Biomol NMR 6:1-10.
16. Keller R. 2004. The computer aided resonance assignment tutorial. 1st edition. Verlag: CANTINA.
17. Danielsson J, Jarvet J, Damberg P, Graslund A. 2004. Two-site binding of beta-cyclodextrin to the Alzheimer Abeta(l-40) peptide measured with combined PFG-NMR diffusion and induced chemical shifts. Biochemistry 43:6261-6269.
18. Otzen DE, Knudsen BR, Aachmann F, Larsen KL, Wimmer R. 2002. Structural basis for cyclo-dextrins' suppression of human growth hormone aggregation. Protein Sci 11:1779-1787.
19. Adachi M, Mikami B, Katsube T, Utsumi S. 1998. Crystal structure of recombinant soybean beta-amylase complexed with beta-cyclodextrin. J Biol Chem 273:19859-19865.
20. Mikami B, Hehre EJ, Sato M, Katsube Y, Hirose M, Morita Y, Sacchettini JC. 1993. The 2.0-A resolution structure of soybean beta-amylase complexed with alpha-cyclodextrin. Biochemistry 32:6836-6845.
21. Miyake K, Hirayama F, Uekama K. 1999. Solubility and mass and nuclear magnetic resonance spectroscopic studies on interaction of cyclosporin A with dimethyl-alpha- and -beta-cyclodextrins in aqueous solution. J Pharm Sci 88:39-45.
22. So MP, Wan TS, Chan TW. 2000. Differentiation of enantiomers using matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom 14:692-695.
23. Qin XR, Abe H, Nakanishi H. 2002. NMR and CD studies on the interaction of Alzheimer beta-amyloid peptide (12-28) with beta-cyclodextrin. Biochem Biophys Res Commun 297:1011-1015.
24. Tavornvipas S, Tajiri S, Hirayama F, Arima H, Uekama K. 2004. Effects of hydrophilic cyclodextrins on aggregation of recombinant human growth hormone. Pharm Res 21:2369-2376.
25. Banga AK, Mitra R. 1993. Minimization of shaking-induced formation of insoluble aggregates of insulin by cyclodextrins. J Drug Target 1:341-345.
26. Merck & Co. Inc. 1996. The Merck Index. 12th ed. New Jersey: Merck & Co. Inc.
27. Wang W. 2005. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm 289:1-30.
28. Clodfelter DK, Pekar AH, Rebhun DM, Destrampe KA, Havel HA, Myers SR, Brader ML. 1998. Effects of non-covalent self-association on the subcutaneous absorption of a therapeutic peptide. Pharm Res 15:254-262.
29. Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W. 2004. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 21:897-903.
30. Onoue S, Iwasa S, Kojima T, Katoh F, Debari K, Koh K, Matsuda Y, Yajima T. 2006. Structural transition of glucagon in the concentrated solution observed by electrophoretic and spectroscopic techniques. J Chromatogr A 1109:167-173.
31. Tokihiro K, Irie T, Uekama K. 1997. Varying effects of cyclodextrin derivatives on aggregation and thermal behavior of insulin in aqueous solution. Chem Pharm Bull 45:525-531.
32. Gratzer WB, Bailey E, Beaven GH. 1967. Conformational states of glucagon. Biochem Biophys Res Commun 28:914-919.
33. Patro SY, Przybycien TM. 1994. Simulations of kinetically irreversible protein aggregate structure. Biophys J 66:1274-1289.
34. Dotsikas Y, Loukas YL. 2002. Kinetic degradation study of insulin complexed with methyl-beta cyclodextrin. Confirmation of complexation with electro-spray mass spectrometry and (1)H NMR. J Pharm Biomed Anal 29:487-494.
35. Wu WM, Wu J, Bodor N. 2002. Effect of 2-hydroxypropyl-beta-cyclodextrin on the solubility, stability, and pharmacological activity of the chemical delivery system of TRH analogs. Pharmazie 57:130-134.
36. Sigurjonsdottir JF, Loftsson T, Masson M. 1999. Influence of cyclodextrins on the stability of the peptide salmon calcitonin in aqueous solution. Int J Pharm 186:205-213.
37. Cleland JL, Langer R. 1994. Formulation and delivery of proteins and peptides. 1st edition. Washington, DC: American Chemical Society.
38. Meyer JD, Ho B, Manning MC. 2002. Effects of conformation on the chemical stability of pharmaceutically relevant polypeptides. Pharm Biotechnol 13:85-107.